Coronary Stents Market Type (Bare-Metal Stents, Drug-Eluting Stents, Bioabsorbable Stents) Based on Mode of Delivery(Balloon-Expandable Stents, Self-Expanding Stents), End-User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers), By Geography, Segment revenue estimation, Forecast: 2021-2030

Published On: Dec-2021 Base Year: 2021 No Of Pages: 140 Historical Data: 2015 - 2019 Formats: PDF Report ID: 33660729

Industry Statistics and Insights

The global coronary stents market will witness a robust CAGR of 4.78%, valued at $8.56 billion in 2021, expected to appreciate and reach $13.03 billion by 2030, confirms Strategic Market Research. Coronary stents are flexible mesh tubes inserted into the arteries to substantially improve the overall blood flow process and prevent the heart muscles from further damage. It is widely implemented during a surgical procedure to keep the arteries open and effectively prevent them from getting blood clogged. According to World Health Organisation, cardiovascular diseases are one of the leading causes of mortality, resulting in up to 18 million deaths each year, thus resulting in approximately 32.43% of the total number of deaths worldwide. Furthermore, one-third of these deaths occur among people under 70 years of age. Therefore, the continuous rising prevalence of cardiovascular diseases (CVDs), such as heart attack and stroke, together with the growing geriatric population, is guaranteed to propel the growth of the Coronary Stent Market during the forecasted period.

Global Coronary Stents Market infographic segmentation coverage 2020-2030

COVID-19 Impact

The COVID-19 outbreak had a considerable impact on the overall market growth rate. This deadly pandemic has led to a substantial rise in myocardial infarction affecting the overall cardiovascular system, especially of the elderly population who were victims of the Covid-19 outbreak. During this period, there is an utmost need for a conservative approach for patients with acute cardiovascular diseases. The invention of some efficient antiproliferative drugs and polymers for controlling, releasing, and allowing adequate endothelialization along with the optimal duration of the antiplatelet regimen will drastically boost the entire market growth amidst the pandemic.

Market Drivers: -

The high increase in the rate of cardiovascular diseases such as stroke and heart attacks, and the continuous rising of the senior population worldwide, are the two main reasons that are widely simulating the growth of this market. The widespread use of Alcohol, Tobacco, and Stress is also considered a pivotal contributor to heart ailments, thereby driving the market growth. The Spike in the number of percutaneous coronary intervention (PCI) methods over the last few years has also contributed immensely to the acceleration process of the overall market growth rate.

Restraints: -

In-stent restenosis (ISR) is the main reason that obstructs this market's growth as it results in gradual re-narrowing of the stented coronary artery lesion because of arterial damage with subsequent neointimal tissue proliferation. The occurrence of in-stent restenosis (ISR) remains an intimidating challenge despite several advancements in coronary intervention technology. Moreover, Angiographic Restonisis is also one of the major problems that have been reported in as many as 50% of the patients within six months of balloon angioplasty surgery. In addition, it has led to repeated target-vessel revascularization in (20-30)% of cardiac patients.

Coronary Stents Market Based on Mode of Delivery Image

Opportunities: -

Coronary angioplasty with stenting is estimated to revolutionize the treatment of arterial diseases. Approximately 30% of patients across the globe will experience restenosis in the future, which can be successfully treated by implementing this highly upgraded and modernized technique.

The new Bioresorbable Vascular Scaffold (BVS) is another widely adopted cardiac surgery method that is expected to witness massive growth in the future. The overall BVS market is growing rapidly at a CAGR of 12.47%, with overall revenue of USD 210.78 Million in 2020. It is expected to gain a significant landmark of USD 539.7 Million in 2028. BVS provides adequate radial support for a long period to avoid early recoil and releases antiproliferative drugs to prevent restenosis.

There has been a rising preference for minimally invasive surgeries (MIS), as it provides shorter hospital stays and facilitates a quick recovery, and this approach will gain substantial market growth in the future. MIS market is expanding steadily with an overall growth rate of 7.51% and is estimated to reach a value of USD 33.667 Billion in 2028.

Market Analysis Of Different Segments Covered in the Report

Based on Type:

Bare-Metal Stents
Drug-Eluting Stents
Bioabsorbable Stents

Based on Mode of Delivery:

Balloon-Expandable Stents
Self-Expanding Stents

Based on End-User:

Hospitals
Cardiac Centers
Ambulatory Surgical Centers (ASCs)

Coronary Stents Market Based on Region Image

Regional Coverage Analysis

North America

US
Canada
Mexico
Rest of North America

Europe

Germany
France
U.K
Netherlands
Switzerland
Finland
Belgium
Russia
Italy
Spain
Turkey
Rest of Europe

Asia Pacific

China
Japan
India
South Korea
Singapore
Malaysia
Australia
Thailand
Indonesia
Philippines
Rest of Asia-Pacific

LAMEA

Brazil
Argentina
Uruguay
Saudi Arabia
Rest of LAMEA

Segments Analysis & Insights

Based on the type, the 'Drug-Eluting Stents (DES)' held the most dominant share as of 2020, with an overall value of USD 6.95 Billion and growing at a CAGR of 8.77%. Factors such as an abrupt increase in adopting a sedentary lifestyle that led to atherosclerosis effectively enhance the Drug-Eluting Stents segment. Moreover, the widespread use of Drug-Eluting Stents (DES) in the geriatric population will lower the risk of restenosis, which is one of the pivotal factors driving this market's growth significantly.

Based on the Mode of Delivery, the 'Balloon-Expandable Stents' segment is expected to dominate the market during the forecasted period owing to the higher rate of stent utilization and an increase in research activities for further improvement of this technology, and growing regulatory approvals.

Based on End Users, the 'Hospitals' segment is estimated to dominate the market owing to the effective and efficient utilization of coronary stents in hospitals. It also lacks well-planned referral networks for responding effectively and efficiently to the population's health needs. For patients without health insurance, the hospital expenditure on coronary stents ranges typically between USD 11,000 to USD 41,000, depending on the type of stent and the length of hospital stay.

Regional Analysis & Insights

North America has the most dominant regional market for coronary stents as of 2020 and is estimated to witness the same trend throughout the foreseeable future. Every year, about 647,000 people in the United States die from heart disease, thus making it one of the leading causes of death. One out of every four deaths occurs due to cardiac diseases. According to WHO, Cardiovascular diseases resulted in the death of almost 30.47 million people in the United States in 2018.

A sedentary lifestyle results have led to obesity and other cardiovascular diseases such as stroke, heart attack, and ischemic heart diseases (IHD), which are driving the market growth of the U.S. Coronary Stent. Also, major innovative techniques in coronary stent technologies, such as the usage of biodegradable materials, and bifurcated stents, have further augmented the overall market growth in the United States.

Asia Pacific is the fastest-growing region with the highest compound annual growth rate (CAGR) during the forecasted period. The mortality rate due to cardiac diseases is rising abruptly in this region. About one-third of the total deaths occur due to cardiovascular diseases. According to WHO, cardiac diseases caused more than 9.4 million deaths in 2016 in the APAC region. Factors like the growing prevalence of cardiac diseases, large population base, low manufacturing costs, and rising acceptance of advanced technologies are expected to drive market growth in this region. Moreover, the growing focus of key market leaders in this region is widely estimated to boost the coronary stents market immensely in the future.

Coronary Stents Market Report Coverage

Report Attribute	Details
Forecast Period	2021 - 2030
Market size value in 2021	USD 8.56 Billion
The revenue forecast in 2030	USD 13.03 Billion
Growth rate	CAGR of approximately 4.78%
The base year for estimation	2021
Historical data	2016 – 2019
Unit	USD Billion, CAGR (2021 - 2028)
Segmentation	Based on Type, Based on Mode of Delivery, End-User, and Regions.
Based on Type	Bare-Metal Stents, Drug-Eluting Stents, Bioabsorbable Stents.
Based on Mode of Delivery	Balloon-Expandable Stents, Self-Expanding Stents.
Based on End-User	Hospitals, Cardiac Centers, Ambulatory Surgical Centers (ASCs).
Based on Region	North America, Europe, Asia Pacific, LAMIA.
Country Scope	U.S, Canada, France, Germany, U.K, China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc.
Company Usability Profiles	Medtronic plc, Biosensors International Group Limited, Abbott, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, Cook Medical, B. Braun Melsungen AG, Terumo Corporation, Vascular Concepts, STENTYS SA. MicroPort Scientific Corporation, Meril Life Sciences Pvt. Ltd, Transluminal.
Pricing and purchase options	Avail of customized purchase options to meet your exact research needs.

Global Coronary Stents Market Competitive Landscape Analysis

The competitive landscape analysis provides adequate details on the major competitors that are prevailing in the market environment. The comparison is performed based on the company overview, the overall potential of the market, investment in R&D, total revenue generated, market initiatives, company financials, strengths and weaknesses, production sites and facilities, production capacity, etc.

Medtronic plc
Biosensors International Group Limited
Abbott
Boston Scientific Corporation
BIOTRONIK SE & Co. KG
Cook Medical
B. Braun Melsungen AG
Terumo Corporation
Vascular Concepts
STENTYS SA
MicroPort Scientific Corporation
Meril Life Sciences Pvt. Ltd
Translumina

Recent Developments

On August 10th, 2022, a group of scientists from Leesburg developed a highly efficient subtraction technique for the purpose of coronary-stent evaluation. It was discovered that this technique required the combination of DLR, i.e., deep learning reconstruction. This combination yielded highly efficient diagnostic performance for detecting stent restenosis by the coronary CTA.

In 2018, Cook Medical received FDA approval for launching the first five mm diameter SFA drug-eluting stent. It is implemented for the treatment of vessels which are as small as 4mm in diameter. Also, it will provide an additional option in treating patients with lesions in their superficial femoral arteries (SFAs).
On October 1, 2021, Medtronic Resolute Onyx Drug-Eluting Stent was the first to receive One Month DAPT indication. The Resolute Onyx DES is the one, and only DES proved to be highly safe, effective, and reliable in the United States. Resolute Onyx DES, along with its biocompatible polymer and stent design, is highly effective for patients suffering from cardiac diseases.

Frequently Asked Question About This Report

b: The global coronary stents market size was $8.56 Bn in 2021 and is predicted to reach $13.03 Bn by 2030, with a CAGR of 4.78%.

b: North America significantly dominated the market with a share of 34.7% in 2020. This is attributed to the increasing prevalence of cardiovascular diseases like heart attack, stroke, ischemic heart diseases, and consumers increased focus for better and effective treatment.

b: Major factors that are effectively and efficiently driving the market growth include the continuous rising prevalence of cardiovascular diseases (CVDs) such as heart attack and stroke, growing geriatric population, rising occurrence for minimally invasive surgeries (MIS), and a drastic increase in the number of PCI methods.

b: The global coronary stents market is expected to grow at a compound annual growth rate (CAGR) of 4.78% from 2021 to 2030 to reach USD13.03 billion by 2030.

b: Some of the pivotal players in the market include Abbott, C. R. Bard Inc., Terumo Corporation, Medtronic, Boston Scientific, Cook Medical, and MicroPort Scientific Corporation.

Sources

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583537/

https://health.costhelper.com/stents.html

https://www.healthline.com/health/heart-disease/statistics

https://www.who.int/health-topics/cardiovascular-diseases